Another study designed PROTACs against the m6A-RNA writer METTL3-METTL14 by using UZH2 and Cereblon (CRBN) ligand, achieving substantial METTL3−14 degradation in multiple AML cell lines.49 This evidence concerns the gene CRBN and acute myeloid leukemia.